Menu Search
Equities

Biocytogen Pharmaceuticals Beijing Co Ltd

2315:HKG.HZ

Biocytogen Pharmaceuticals Beijing Co Ltd

Actions
  • Price (HKD)5.67
  • Today's Change-0.33 / -5.50%
  • Shares traded131.50k
  • 1 Year change-56.11%
  • Beta--
Data delayed at least 15 minutes, as of Nov 22 2024 08:08 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Biocytogen Pharmaceuticals Beijing Co Ltd is a China-based company mainly engaged in drug development business and preclinical research. The Company operates its business through five segments. The Gene-editing Services segment provides the customized gene-editing services based on animals as well as cells. The Pre-clinical Pharmacology and Efficacy Evaluation segment provides preclinical pharmacology services for the evaluation of drug efficacy and toxicity. The Animal Models Selling segment breeds and sells the animal models for the external and internal use. The Antibody Development segment utilises its antibody discovery platforms to identify antibodies which have the potential to become drug candidates. The Innovative Drugs Development segment is engaged in research and development of innovative drugs with a focus on oncology and autoimmune disease therapeutics.

  • Revenue in HKD (TTM)859.97m
  • Net income in HKD-261.91m
  • Incorporated2009
  • Employees1.04k
  • Location
    Biocytogen Pharmaceuticals Beijing Co LtdNo. 12Baocan South Street, Daxing DistrictBeijing 101111ChinaCHN
  • Phone+86 1 056967666
  • Fax+86 1 056315306
  • Websitehttps://www.biocytogen.com.cn/
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.